Described herein are methods for the induction of a TH2 immune response and for the treatment and/or prevention of diseases associated with pathological immune responses and parasitic infection.

The present invention pertains to the field of recombinant protein production. Novel expression cassettes comprising elements of the human globin gene clusters are provided which show enhanced expression rates of proteins or polypeptides of interest.

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-.sub.2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as adrenergin receptor agonists, adrenergin receptor antagonists, and/or glycemic control agents.

mRNA polymer complexes and drug delivery systems are disclosed herein that include a cationic polymer electrostatically complexed to an mRNA molecule that encodes a desired protein. Also disclosed herein are methods of treating as well as methods of slowing the loss of, increasing, and/or maintaining lean muscle mass in a subject, such as using mRNA polymer complexes and drug delivery systems.

Disclosed are components and systems for cell-free glycoprotein synthesis (CFGpS). In particular, the components and systems include and utilize prokaryotic cell lysates from engineered prokaryotic cell strains that have been engineered to enable cell-free synthesis of glycoproteins.

The invention is in the field of medical treatments, in particular the treatment of humans, more in particular humans with calcium deposition diseases. In one aspect, the invention provides polypeptides that prevent or decrease the precipitation of calcium crystals in the human body, also known as ectopic calcification. More in particular, the invention relates to a circular polypeptide consisting of an amino acid sequence according to SEQ ID NO: 1, wherein the amino acids are D-amino acids, pharmaceutical compositions comprising a polypeptide as described herein and their use in the treatment of a disease selected from the group consisting of osteoarthritis, frozen shoulder syndrome, heterotopic ossification, vascular calcification, kidney stones and calcinosis.

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-?.sub.2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as ? adrenergin receptor agonists, ? adrenergin receptor antagonists, and/or glycemic control agents.

A process is provided, comprising reacting a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne, wherein the (hetero)aryl 1,3-dipole compound comprises a 1,3-dipole functional group bonded to a (hetero)aryl group, and wherein the (hetero)aryl 1,3-dipole compound is a (hetero)aryl azide or a (hetero)aryl diazo compound; wherein: (i) the (hetero)aryl group of the (hetero)aryl 1,3-dipole compound comprises a substituent (ii) the (hetero)aryl group of the (hetero)aryl 1,3-dipole compound is an electron-poor (hetero)aryl group
and wherein the (hetero)cycloalkyne is a (hetero)cyclooctyne or a (hetero)cyclononyne according to Formula (1). The invention also relates to the products obtainable by the process according to the invention.

The inventive subject matter relates to novel antibodies to lacritin splice variants, improved methods for detecting lacritin splice variants, and methods for diagnosing Sjgren's Syndrome.

A technique for enhancing functions such as proliferation ability and imparting an activity of capturing cytokines which may cause side effects in immune cells for use in the adoptive immunotherapy is disclosed. A chimeric cytokine receptor having a ligand-binding region with a cytokine-binding region of a cytokine receptor at the N-terminal side and a T-cell activating region having the transmembrane domain and the intracellular domain of an IL-7 receptor chain at the C-terminal side is provided. Amino acid sequence SEQ ID NO: 1 of the transmembrane domain has an insertion of one of: (a) amino acid sequence SEQ ID NO: 2 between positions 243 and 244, (b) amino acid sequence SEQ ID NO: 3 between positions 241 and 242, (c) amino acid sequence SEQ ID NO: 4 between positions 244 and 245, (d) amino acid sequence of SEQ ID NO: 5 between positions 244 and position 245, or (e) amino acid sequence of SEQ ID NO: 6 between positions 246 and 247.